Embecta hits multi-year lows on GLP-1 fears, but offers 6%+ yield and deep value. Read the latest analysis on the stock and its announced acquisition of Owen Mumford here.

Becton, Dickinson and Co.’s board of directors approved the company’s diabetes spinoff, and set a date of April 1 for the move. The announcement of Embecta Corp.’s approval came Feb. 1, along with a ...

Embecta Corp. EMBC recently announced a definitive agreement to acquire Owen Mumford Holdings Limited, a pioneer in developing advanced drug delivery systems and medical device solutions, making a ...

PARSIPPANY, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta"; "The Company") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host its ...

Embecta Corp., a global diabetes care company with a century-long history in insulin delivery, will host an Analyst and Investor Day on May 22, 2025, in New York City. The event, which will run from 9 ...

Embecta Corp. company and executive profile by Barron's. View the latest EMBC company infomation and executive bios.

Shares of Embecta stock opened at $12.30 on Wednesday. The firm’s 50 day simple moving average is $13.73 and its two-hundred day simple moving average is $15.98. The firm has a market capitalization ...

CEO Devdatt Kurdikar highlighted the completion of Embecta’s patch pump program and a restructuring plan to enhance profitability and free cash flow. "We completed the implementation of our own ERP ...

Dev will begin by providing an overview of Embecta, our strategic priorities for 2023, and some remarks on the overall performance of our business during the second quarter. Jake will then provide a ...